Shareholding disclosure

Rudolf Dr. h.c. Maag

Declared position

Threshold

Fell below threshold

Timeline

Published

10.10.2012

Transaction

05.10.2012

Voting rights breakdown

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TACA800093

Beneficial owner

Rudolf Dr. h.c. Maag

Declared address

Rudolf Dr. h.c. Maag, 4102 Binningen

Gesellschaft zu 100 % beherrscht von R. Maag

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Rudolf Dr. h.c. Maag

Basilea Pharmaceutica AG, Allschwil10.10.2012TACA800093

Disclosure summary

Rudolf Dr. h.c. Maag disclosed a holding in Basilea Pharmaceutica AG, Allschwil that fell below the publication threshold, published by SIX Exchange Regulation on 10.10.2012, at 3% of voting rights. Notice category: Single shareholder.

Disclosed position

Below threshold

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Rudolf Dr. h.c. Maag disclosed a holding in Basilea Pharmaceutica AG, Allschwil, published on 10.10.2012.

Publication date10.10.2012

Transaction date05.10.2012

Issuing companyBasilea Pharmaceutica AG, Allschwil

Beneficial ownerRudolf Dr. h.c. Maag

Declared addressRudolf Dr. h.c. Maag, 4102 Binningen

CategorySingle shareholder

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

ExchangeXSWX

Notification IDTACA800093

Conditions

Gesellschaft zu 100 % beherrscht von R. Maag

Source: SIX Exchange Regulation · Publication date: 10.10.2012

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open